Schering Plough to Present at GTCbio`s 6th Cytokines and Inflammation (January 28-29, 2008, Orlando, Florida)
Released on: January 7, 2008, 10:58 am
Press Release Author: GTCBIO
Industry: Pharmaceuticals
Press Release Summary: Jianhua Chao, Principal Scientist of Discovery Chemical Research at Schering-Plough will give a presentation entitled "Potent, Orally Active CXCR2-CXCR1 Antagonists as Anti-inflammatory Therapy" at GTCbio's 6th Cytokines and Inflammation. (January 28-29, 2008, Orlando, Florida)
Press Release Body: FOR IMMEDIATE RELEASE January 7, 2008
Schering Plough to Present at GTCbio's 6th Cytokines and Inflammation (January 28-29, 2008, Orlando, Florida)
Jianhua Chao, Principal Scientist of Discovery Chemical Research at Schering-Plough will give a presentation entitled "Potent, Orally Active CXCR2-CXCR1 Antagonists as Anti-inflammatory Therapy" at GTCbio's 6th Cytokines and Inflammation. (January 28-29, 2008, Orlando, Florida)
Dr. Jianhua Chao is a Principal Scientist of Discovery Chemical Research at Schering-Plough Research Institute. She joined SPRI at the end of 2000 as a Senior Scientist shortly after her completion of Ph.D. study. Over the past seven years, she has been actively involved in a number of discovery research projects ranging across allergy, pulmonary, inflammation, and CNS therapy areas. She has also played a leadership role in a couple of Schering-Plough /Pharmacopeia collaboration projects. In the CXCR2 antagonists program, Dr. Chao and her colleagues have discovered and developed a novel series of receptor antagonists, one of which has been selected as a clinical candidate and being progressed in phase II studies for the treatment of chronic inflammatory disorders. She is an inventor / coinventor of eighteen patents & patent applications, and an author / coauthor of five scientific publications. Dr. Chao received her Ph.D. degree in Synthetic Organic Chemistry from Florida State University under the direction of Professor Robert A. Holton. Her graduate work focused on the total synthesis of complex natural product Taxol and its 1-deoxy analog. Her strong interest is to apply synthetic capabilities into probing biological targets, design and develop new medications for people and society
The conference also features presentations from other leading organizations such as Amgen, AstraZeneca, Biogen Idec, FDA, Genentech, Merck, NIH, Novo Nordisk, Pfizer, Roche, and many more. The full agenda is available online at www.gtcbio.com.
GTCbio's 6th Cytokines and Inflammation conference will take place on January 28-29, 2008 at the Orlando Metropolitan Resort in Orlando, Florida and will cover Cytokines Signaling and Regulation, Inflammation and Cancer, Technological Developments in Cytokines Biology, Chemokines, and Targeting of Cytokine Receptors
For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/userAgenda.aspx?id=115
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
2025
